Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.36 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.36 |
| ▸ | KRAS | P01116 | 2/20 | 0.33 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2997951 | 0.89 | PTGDR2 (0.36) | PIM1PIM2KRASPTGDR2ALDH3A1 | |
| SCHEMBL2985981 | 0.88 | PIM1 (0.36) | PIM1PIM2PTGDR2TSHRALDH3A1 | |
| SCHEMBL2987057 | 0.84 | PTGDR2 (0.38) | PIM1PIM2PTGDR2 | |
| SCHEMBL9987630 | 0.84 | PIM1 (0.36) | PIM1PIM2PTGDR2TSHRALDH3A1 | |
| SCHEMBL13103442 | 0.83 | L3MBTL1 (0.37) | PIM1PIM2PTGDR2TSHRALDH3A1 | |
| SCHEMBL2991242 | 0.83 | PIM1 (0.35) | PIM1PIM2PTGDR2TSHRALDH3A1 | |
| SCHEMBL2988487 | 0.83 | PIM1 (0.35) | PIM1PIM2PTGDR2TSHRALDH3A1 | |
| SCHEMBL2993710 | 0.83 | PIM1 (0.35) | PIM1PIM2PTGDR2TSHRALDH3A1 | |
| SCHEMBL2989166 | 0.82 | PIM1 (0.35) | PIM1PIM2PTGDR2TSHRALDH3A1 | |
| SCHEMBL2995374 | 0.81 | PIM1 (0.34) | PIM1PIM2PTGDR2TSHRALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256141-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | AVENTIS PHARMA S.A. (FR) | 2010-10-07 | — | — | US | disclosed |
| US-7786114-B2 | Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2010-08-31 | — | — | US | disclosed |
| US-20080045561-A1 | Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors | AVENTIS PHARMA S.A. (FR) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045561-A1 | Novel Bis-Azaindole Derivatives, Preparation And Pharmaceutical Use Thereof As Kinase Inhibitors | BRSK2, KSR2, CDK2 | PIM1 695/4885PIM2 607/4885KRAS 275/4885 |
| US-20100256141-A1 | NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS | BRSK2, KSR2, CDK2 | PIM1 695/4885PIM2 607/4885KRAS 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.